Lilly Biotechnology Center in San Diego, California on March 1, 2023.
Mike Blake | Reuters
Eli Lilly On Thursday, he reported on mixed results for the fourth quarter because the sale of her blockbuster weight loss of Zepbound and diabetes Mounjaro has grown, but recorded lower prices.
The data was in line with the preliminary results Eli Lilly shared in January, which disappointed investors. Eli Lilly reduced its income from 2024As the demand for weight loss said, diabetes will not meet his exalted expectations.
The three -month three -month earnings surpassed Wall Street estimates, but the sale was just short.
The pharmaceutical giant also issued fiscal guidelines for profit of 2025 from $ 22.05 to $ 23.55 per share, which is in line with what analysts expected. Eli Lilly repeated her fiscal sales guidelines of $ 58 billion of $ 58 billion.
Here’s what Eli Lilly reported in the fourth quarter compared to what Wall Street expected, based on research by analysts from LSEG:
- Earnings per share: $ 5,32 adjusted to $ 4.95
- Income: Expected $ 13.53 billion compared to $ 13.57 billion
The company announced revenue in the fourth quarter of $ 13.53 billion, which is 45% compared to the same period a year ago.
The pharmaceutical giant has booked a net revenue of $ 4.41 billion, or $ 4.88 per share, in the fourth quarter. This is compared to profit of $ 2.19 billion, or $ 2.42 per share, a year earlier.
With the exception of one -off items associated with the value of intangible assets and other adjustments, Eli Lilly made a $ 5,32 earnings per share for the fourth quarter of 2024.
This story develops. Please check updates.
